Profound Medical Corp. (PROF) Financial Analysis & Valuation | Quarter Chart
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finl... more
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical devic... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $251.09M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | CA | CEO | Arun Swarup Menawat |
| IPO Date | 2019-10-29 | CAGR | — |
| Employees | 162 | Website | www.profoundmedical.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PROF chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $189.92M | P/E | -7.05 | Forward P/E | -9.66 | PEG | — |
| P/S | 0.03 | P/B | 0.02 | P/CF | -0.02 | P/FCF | -0.02 |
| Sales | $19.01M | Sales 1Y | 62.18% | Sales 3Y | 138.4% | Sales 5Y | 102.24% |
| EPS | $-0.98 | EPS 1Y | -68.03% | EPS 3Y | -65.69% | EPS 5Y | -66.43% |
| Sales QoQ | -52.82% | EPS QoQ | -236.84% | Sales QoQ Avg | 21.86% | EPS QoQ Avg | -78.64% |
| Gross Margin | 71.04% | Operating Margin | -202.52% | Profit Margin | -206.94% | ROCE | -60.41% |
| ROA | -53% | ROE | -79% | Altman Z Score | 11.07 | Piotroski Score | 2 |
| Current Ratio | 6.56 | Quick Ratio | 5.71 | Cash Ratio | 4.74 | Op. CF Ratio | -1.24 |
| Debt/Equity | 0.13 | Debt/Assets | 0.07 | Lt Debt/Equity | 0.09 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | 0.6 | Asset Turnover | 0.26 | Receivables Turnover | 1.99 |
| Enterprise Value | $189.92M | P/E Ratio | -7.05 |
| Forward P/E | -9.66 | PEG Ratio | — |
| P/S Ratio | 0.03 | P/B Ratio | 0.02 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-0.98 | EPS Growth 1Y | -68.03% |
| EPS Growth 3Y | -65.69% | EPS Growth 5Y | -66.43% |
| Revenue Growth 1Y | 62.18% | Gross Margin | 71.04% |
| Operating Margin | -202.52% | Profit Margin | -206.94% |
| ROE | -79% | ROA | -53% |
| ROCE | -60.41% | Current Ratio | 6.56 |
| Quick Ratio | 5.71 | Cash Ratio | 4.74 |
| Debt/Equity | 0.13 | Interest Coverage | — |
| Altman Z Score | 11.07 | Piotroski Score | 2 |
Profound Medical Corp. (PROF) valuation & financials
Profound Medical Corp. (PROF) has a market capitalization of $251.09M and trades at a price-to-earnings ratio of -7.0. It operates in the Healthcare sector (Medical - Devices).
Profound Medical Corp.'s revenue grew +62.2% over the last year.
Profound Medical Corp.'s next earnings report is scheduled for November 12, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.23. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)